Traditional Chinese medicine composition for treating pulmonary arterial hypertension right heart failure and preparation method thereof

Abstract

The invention provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension right heart failure, which is characterized in that the traditional Chinese medicine composition is prepared from the following raw material medicines: safflower carthamus, polygonum cuspidatum, semen lepidii, white mulberry root-bark and astragalus membranaceus. Various components in the traditional Chinese medicine composition are scientific in compatibility and play a synergistic effect, the cardio-pulmonary function of a right heart failure rat suffering from pulmonary arterial hypertension can be improved, the hemodynamics of pulmonary artery can be improved, the pathological damage and fibrosis degree of cardiac muscle tissue can be relieved, the inflammation level can be reduced, and the remarkable treatment effect on the right heart failure suffering from pulmonary arterial hypertension can be achieved; the clinical application value is higher, and the medical application prospect is wide.

Description

TECHNICAL FIELD

[0001] The application belongs to the field of traditional Chinese medicine and the field of cardiovascular disease, and specifically provides a traditional Chinese medicine composition for treating pulmonary hypertension right heart failure and a preparation method thereof. BACKGROUND

[0002] Pulmonary hypertension (PH) is a progressive pulmonary vascular disease that exists worldwide and has a high mortality rate. The main features of this disease are increased pulmonary vascular resistance and pulmonary vascular remodeling, which in turn increases the right ventricular afterload and eventually leads to right heart failure and even death. The pathogenesis of PH is complex, and it is the result of the combined action of multiple factors and multiple links. Inflammation, vasoactive molecules, ion channels, and genetic factors are all involved in the development of PH. However, regardless of the cause of PH, patients have similar hemodynamic changes and clinical symptoms, and the structural and functional changes of the right ventricle are an important cause of pulmonary hypertension right heart failure. In terms of treatment, the current PH is mainly based on basic treatment and specific treatment. The basic treatment is mainly symptomatic treatment such as diuresis and oxygen therapy, and the specific treatment includes target therapy such as endothelin receptor antagonists and prostacyclin pathway. However, the survival prognosis of patients is still poor, and the serious consequences caused by multiple organ damage, especially heart failure, significantly increase the difficulty of treatment, which has become a clinical problem that needs to be solved urgently.

[0003] Traditional Chinese medicine has accumulated rich clinical experience in the treatment of pulmonary hypertension. The efficacy of traditional Chinese medicine currently used in clinical practice for pulmonary hypertension right heart failure is not certain, especially the long-term effect of medication is poor. The present application aims to provide a pulmonary hypertension right heart failure treatment drug with accurate therapeutic effect. SUMMARY

[0004] In view of the above, the applicant puts forward the theory of "toxicity and stasis causing disease" based on years of clinical experience and modern pharmacological research. The toxicity in traditional Chinese medicine is divided into internal and external. External toxicity refers to the toxic evil caused by the external abnormal climate changes, including wind evil, cold evil, heat evil, damp evil, dry evil and fire evil. Internal toxicity refers to the toxic evil caused by the disorder of viscera, meridians and blood, and the imbalance of yin and yang. The so-called "stasis" refers to the pathological product caused by the accumulation of blood due to various reasons. Toxicity and stasis are closely related and closely connected. Toxicity is the basis and condition of stasis. Toxic evil consumes blood and liquid to form stasis. Stasis coagulates and obstructs, leading to the production of pulmonary hypertension. The infiltration and destruction of lung inflammation is the main starting link of PH. Chronic inflammation can not only cause endothelial damage, leading to thickening of the tube wall and narrowing of the tube lumen, but also can cause blood to be in a high coagulation state, which has an important influence on the change of pulmonary hemodynamics. Inflammation corresponds to the "toxicity" discussed in traditional Chinese medicine theory, and the high coagulation state caused by the change of blood rheology corresponds to the "stasis" in traditional Chinese medicine theory. Therefore, it is of great significance to treat COPD combined with PH with traditional Chinese medicine with the functions of clearing heat and resolving toxicity and promoting blood circulation to remove blood stasis. And many modern studies have confirmed that traditional Chinese medicine with the functions of clearing heat and resolving toxicity and promoting blood circulation to remove blood stasis has good effects of anti-inflammatory, dilating blood vessels and anticoagulation. Based on this, the applicant proposes the present application to treat pulmonary hypertension. The present application takes clearing heat and resolving toxicity and promoting blood circulation to remove blood stasis as the therapeutic method, and is mainly used for treating heat-toxin accumulation and blood stasis. The clinical symptoms include shortness of breath, aggravated after exercise, cough, chest tightness and / or chest pain, purple complexion, cyanosis of lips and nails, dry mouth, fatigue, purple tongue, thin white fur, and fine and astringent or weak pulse.

[0005] Safflower in the prescription can disperse and warm, and is used for blood, which is the main drug for promoting blood circulation to remove blood stasis. It can effectively dredge the stasis in lung, heart and whole body, improve microcirculation, reduce pulmonary vascular resistance, and relieve chest pain, cyanosis and other symptoms. Giant knotweed has the functions of promoting blood circulation to remove blood stasis and clearing heat and resolving toxicity, and can clear the heat caused by long-term stasis or external heat. It can also treat cough and phlegm, and has an auxiliary therapeutic effect on the symptoms of cough and phlegm in patients with pulmonary hypertension. It is the ministerial drug. The combination of Semen Platycladi and White Mulberry Bark can clear lung and relieve asthma and edema. According to the clinical observation, pulmonary hypertension is often accompanied by water and fluid retention in the lung. The combination of the two drugs can enhance the functions of clearing lung and removing fluid, relieving asthma and edema, and is the auxiliary drug. Pulmonary hypertension is a chronic disease, and people with long-term illness often consume and damage the healthy qi, leading to qi deficiency. In addition, "qi deficiency leads to water retention", and the deficiency of qi can lead to the retention of water and fluid. Therefore, Huangqi is added to tonify qi and ascend yang, and remove water and edema. The whole prescription takes into account the main and secondary, treats toxicity and stasis, regulates qi and blood, and uses cold and warm together, which has good clinical effect.

[0006] On the one hand, the present application provides a traditional Chinese medicine composition for treating pulmonary hypertension and right heart failure, which is prepared from raw materials including safflower, giant knotweed, Semen Platycladi, White Mulberry Bark and Huangqi.

[0007] Further, the traditional Chinese medicine composition is prepared from 6-15 parts by weight of safflower, 6-15 parts by weight of giant knotweed, 8-20 parts by weight of Eutrema wasabi Maxim, 10-30 parts by weight of mulberry bark, and 10-30 parts by weight of astragalus.

[0008] Further, the traditional Chinese medicine composition is prepared from 10 parts by weight of safflower, 10 parts by weight of giant knotweed, 12 parts by weight of Eutrema wasabi Maxim, 15 parts by weight of mulberry bark, and 15 parts by weight of astragalus.

[0009] Further, the traditional Chinese medicine composition is prepared according to the following method: weighing the required amount of medicinal materials; decocting 2-4 times, each time adding 10-15 times the amount of water and decocting for 20-60 min; filtering and combining the water decoction and concentrating to 2-3 g of crude drug per 1 g of extract.

[0010] Further, the traditional Chinese medicine composition is prepared according to the following method: weighing the required amount of medicinal materials; decocting 3 times, each time adding 14 times the amount of water and decocting for 30 min; filtering and combining the water decoction and concentrating to 2.72 g.

[0011] Further, the traditional Chinese medicine composition further comprises a pharmaceutically acceptable excipient.

[0012] Further, the traditional Chinese medicine composition is an oral liquid, a mixture, a decoction, a pill, a capsule, a tablet, a granule, or a powder.

[0013] The skilled person can select suitable excipients according to the dosage form, including but not limited to fillers, binders, sustained-release agents, lubricants, coloring agents, taste-masking agents, flavoring agents, coating agents, capsules, solvents, co-solvents, pH adjustors, antioxidants, preservatives, etc.

[0014] In another aspect, the present application provides the use of the above-mentioned traditional Chinese medicine composition in the preparation of a drug for treating or preventing pulmonary arterial hypertension and right heart failure.

[0015] Further, the drug has one or more of the following effects:

[0016] (1) improving the hemodynamics of the pulmonary artery;

[0017] (2) improving the structure and function of the right heart;

[0018] (3) reducing the pathological damage to myocardial tissue;

[0019] (4) the degree of collagen deposition and fibrosis;

[0020] (5) reducing the level of serum heart failure markers;

[0021] (6) reducing the level of inflammation.

[0022] Further, the heart failure marker is selected from ANP and / or BNP.

[0023] Further, the reducing inflammation level is reducing IL18 and / or TNF-α.

[0024] In another aspect, the application provides a preparation method of the traditional Chinese medicine composition for treating pulmonary hypertension right heart failure, the method comprising: weighing the required amount of medicinal materials; decocting 2-4 times, each time adding 10-15 times of water and decocting for 20-60 min; filtering and combining the water decoction and concentrating to 2-3 g of crude drug per 1 g of extract.

[0025] Further, the method comprises: weighing the required amount of medicinal materials; decocting 3 times, each time adding 14 times of water and decocting for 30 min; filtering and combining the water decoction and concentrating to 2.72 g.

[0026] The traditional Chinese medicine composition in the application is prepared under the guidance of traditional Chinese medicine theory and clinical trials, and the medicinal materials are carefully selected. The safflower in the traditional Chinese medicine composition can activate blood circulation to remove blood stasis, the giant knotweed can detoxify and remove blood stasis, the astragalus membranaceus has the effects of tonifying qi and activating blood, and the platycladus orientalis and mulberry bark have the effects of relieving lung and asthma, promoting water and reducing swelling. Modern pharmacological research shows that the multiple medicinal materials have the effects of improving heart function and lung diseases. The medicinal components in the composition of the application are dialectically matched, and the effects are complementary. The composition has the effects of tonifying qi, activating blood, detoxifying and removing blood stasis, and has good effects on treating or preventing pulmonary hypertension right heart failure. The composition can significantly improve the hemodynamics of the pulmonary artery and the heart function of the pulmonary hypertension right heart failure rats, reduce the pathological damage and fibrosis degree of the myocardial tissue, has small toxic and side effects, provides a new drug selection for the treatment of pulmonary hypertension right heart failure, and has a wide medical application prospect. BRIEF DESCRIPTION OF DRAWINGS

[0027] Figure 1 is the total ion chromatogram of the extract of the traditional Chinese medicine composition determined by UPLC-Q-TOF-MS / MS method;

[0028] Figure 2 is the echocardiogram image;

[0029] Figure 3 is the echocardiogram analysis result;

[0030] Figure 4 is the effect of the traditional Chinese medicine composition on the histological changes of the mouse heart tissue observed by HE staining method;

[0031] Figure 5 is the effect of the traditional Chinese medicine composition on the myocardial fibrosis caused by pulmonary hypertension observed by Masoon staining method;

[0032] Figure 6To observe the effect of the Chinese medicine composition on the collagen deposition of heart tissue caused by pulmonary hypertension by Sirius Red staining method;

[0033] Figure 7 To observe the effect of the Chinese medicine composition on the concentration of (A) ANP, (B) BNP, (C) IL18, and (D) TNF-α in the serum of the PH rats. DETAILED DESCRIPTION

[0034] Preparation of the Chinese medicine composition in Example 1 and identification of components thereof

[0035] Experimental drugs:

[0036] The Chinese medicine composition used in the present application comprises safflower 10g, giant knotweed 10g, Eutrema latifolium 12g, mulberry bark 15g, and astragalus 15g. The medicinal materials in the prescription (62g per set) are weighed according to the proportion, decocted for 3 times, each time with 14 times of water for 30min, and then the water decoction is filtered and combined and concentrated to obtain 2.72g of raw medicine per 1g of extract.

[0037] Identification of chemical components of the Chinese medicine composition

[0038] The chemical components of the medicine are identified by UPLC-Q-TOF-MS / MS method. The extract of the Chinese medicine composition is dissolved with methanol, centrifuged, filtered, and then mass spectrum data is collected in the positive ion mode. The total ion current chromatogram of UPLC-Q-TOF-MS / MS in the positive ion mode is shown in Figure 1 Table 1, and the identified compounds are shown in Table 1.

[0039] The mass spectrometry conditions are as follows: positive ion mode, UPLC-Q-TOF-MS / MS (Waters, USA) chromatographic analysis is controlled by an Acquity UPLC-PDA system, a time-of-flight mass spectrometer is controlled by a G2-XS QTOF system, a positive ion mode is selected, ESI is used as an ionization source, the desolvation gas temperature is 450°C, the gas flow rate is 700 L / h, the ion source temperature is 80°C, leucine enkephalin is selected as a mass lock standard ([M+H]+ = 556.2771), the concentration is set to 200 L / mL, the sample injection flow rate is 10 μL / min. The original data is selected in a Continuum mode, the mass spectrometry data acquisition range is m / z 50-1500, the capillary voltage value is 2.0 kV, the cone hole voltage value is 40 V, the collision energy is 6 eV, the energy scan range is 20-40 eV, and the data is processed by MassLynx 4.1 software. The UPLC chromatography conditions are as follows: positive ion mode, chromatographic column: ACQUITY UPLC (R) BEH C18 (2.1 mm x 50 mm, 1.7 μm); detection wavelength: 210, 254 nm; sample injection amount: 6 μL; column temperature: 35°C; flow rate: 0.3 mL / min; mobile phase: acetonitrile (A, with 0.1% formic acid)-water (B, with 0.1% formic acid). Elution method: 0-2 min, 5% (A); 2-23 min, 5%-98% (A); 23-24 min, 98%-5% (A); 24-26 min, 5% (A).

[0040] Table 1 Compounds identified by UPLC-Q-TOF-MS / MS

[0041]

[0042]

[0043]

[0044] Pharmacodynamic effect of the traditional Chinese medicine composition on pulmonary arterial hypertension and right heart failure in rats in Example 2

[0045] Establishment of a pulmonary arterial hypertension and right heart failure model in rats

[0046] Seventy SPF SD male rats, weighing 160-180 g, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (license number: SYXK (jing) 2023-0008), and were raised in the animal room of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, at a temperature of 22±2°C, with a moderate humidity of 50%-60% and a 12-hour light-dark cycle. The rats were allowed to eat and drink freely, and the experimental process was in line with the regulations of the Animal Committee of Peking Union Medical College Hospital.

[0047] 10 SD rats were randomly selected as control group (Control) and single administration group (Control + traditional Chinese medicine composition 4.1 g·kg -1 -1), the rest of the 50 rats were injected with 60 mg / kg MCT once, and 14 days later, the success of the modeling was observed. The PH rats were randomly divided into 5 groups: model group Model (10), Model + traditional Chinese medicine composition (1.025 g·kg -1 -1), Model + traditional Chinese medicine composition (2.05 g·kg -1 -1), Model + traditional Chinese medicine composition (4.1 g·kg -1 -1), Model + furosemide (20 mg·kg -1 -1). The low, medium and high dose groups of traditional Chinese medicine composition, Control + H, Furosemide group were given corresponding drugs by gavage once a day, for 14 days, and the Control group was given the same amount of normal saline by gavage.

[0048] Morphological examination

[0049] After the end of administration, Vevo1100 ultrahigh resolution small animal ultrasound imaging system was used to evaluate the heart and lung function of rats. After the SD rats in each group were anesthetized with pentobarbital sodium (40 mg / kg), they were fixed on the detection plate in supine position, the chest was depilated and coated with appropriate coupling agent, and the ultrasonic heartbeat detection was performed using a 21 MHz probe, and the pulmonary blood outflow at the aortic valve level was recorded using pulsed wave Doppler echo, and the pulmonary artery acceleration time (PAT), pulmonary artery ejection time (PET) were measured, and the tricuspid annular plane systolic excusion (TAPSE) and right ventricular internal dimension (RVID) were measured by M-mode ultrasound.

[0050] After the end of traditional Chinese medicine composition intervention, ultrasonic heartbeat detection was performed on rats in each group (results are shown in Figure 2 ) to observe the pulmonary artery blood flow and right heart function of each group. Figure 3Echocardiography analysis showed that compared with the blank group, the TAPSE of the model group rats was significantly reduced, indicating that the right ventricular systolic function was impaired, which was significantly related to the decrease of cardiac output and the increase of pulmonary vascular resistance. PAT was significantly reduced, indicating that the blood flow acceleration time was shortened and the right ventricular systolic efficiency was decreased. RVID was significantly increased, indicating that the right ventricular wall was thickened due to the dilation caused by right ventricular volume overload or pressure overload. The differences of the above indexes were statistically significant (P<0.05). Compared with the model group, the TAPSE and PAT of the F-M and F-H groups were significantly increased, and the RVID was significantly reduced, indicating that the Chinese medicine composition had a protective effect on the cardiopulmonary function of the right ventricular heart failure rats with pulmonary arterial hypertension.

[0051] As shown in Figure 4 , after the intervention of the Chinese medicine composition ended, the right ventricular tissue of each group of rats was HE stained to observe the therapeutic effect of the Chinese medicine composition on the right heart failure rats with pulmonary arterial hypertension. After HE staining, the myocardial fibers of the Control group were arranged closely and regularly, and the myocardial cells were normal. The myocardial structure of the Control+F-H group was basically the same as that of the Control group, and the myocardial cells were arranged in order without structural disorder. The cytoplasm was evenly stained, and the nuclear morphology was normal without pathological changes. It is indicated that the high-dose intervention drug (F-H) itself has no toxicity or stimulation effect on normal myocardium. Compared with the blank group, the cell arrangement of the model group was obviously disordered, and part of the cells were swollen and necrotic, with karyopyknosis or lysis, accompanied by inflammatory cell infiltration. After the intervention of the Chinese medicine composition, compared with the model group, the myocardial cell arrangement of the F-M and F-H groups tended to be regular, the necrotic cells were further reduced, the myocardial cell swelling and intracellular edema were significantly reduced, and the inflammatory changes of the cells were reduced.

[0052] As shown in Figure 5 , after the intervention of the Chinese medicine composition ended, the right ventricular tissue of each group of rats was Masson stained to observe the therapeutic effect of the Chinese medicine composition on the right heart failure rats with pulmonary arterial hypertension. The myocardial tissue of the Control group was arranged closely and regularly, showing a typical muscle fiber bundle structure, and the red staining was uniform. Only a small amount of fine blue fibers were distributed around the blood vessels or between the muscle bundles, which were normal interstitial components. The myocardial tissue of the Control+F-H group was consistent with that of the Control group, and the red muscle fibers were arranged in order without rupture or dissolution. There was no significant difference in the distribution of blue fibers compared with the Control group, and no abnormal proliferation was found. The high-dose intervention drug (F-H) had no fibrosis-promoting effect on normal myocardium, and had good safety. The red muscle fibers of the Model group were arranged in disorder, and part of them were ruptured or dissolved, and the blue fibers were significantly proliferated, indicating interstitial remodeling and pathological fibrosis. After the intervention of the Chinese medicine composition, compared with the model group, the red muscle fiber rupture area of the F-M and F-H groups was significantly reduced, and the blue collagen fibers were reduced, indicating that the Chinese medicine composition significantly improved fibrosis.

[0053] As shown in Figure 6As shown, after the intervention of the traditional Chinese medicine composition, the right ventricular tissue of each group of rats was subjected to Sirius Red staining to observe the therapeutic effect of the traditional Chinese medicine composition on pulmonary hypertension right heart failure rats. The myocardial tissue structure of the Control group was dense and uniform, arranged in typical bundles, and the yellow staining was clear. Only a small amount of fine red fibers were distributed around the blood vessels or in the muscle bundle space. The myocardial tissue of the Control+F-H group was consistent with the Control group, the yellow muscle fibers were arranged in order, and there was no rupture or dissolution. The distribution of red fibers was not different from the Control group, and there was no abnormal proliferation, suggesting that high-dose intervention drugs (F-H) had no fibrosis side effects on normal myocardium. The yellow muscle fibers of the Model group were arranged in disorder, partially ruptured or dissolved, and the red fibers significantly proliferated, infiltrated the muscle bundle and replaced part of the myocardial area, suggesting severe interstitial remodeling. After the intervention of the traditional Chinese medicine composition, compared with the model group, the yellow muscle fibers tended to be regular, the proportion of red fibers decreased, and only a small amount of fine fibers were distributed along the muscle bundle, suggesting that the traditional Chinese medicine composition significantly improved fibrosis and improved cardiac collagen deposition.

[0054] Mechanism of the traditional Chinese medicine composition in treating pulmonary hypertension right heart failure rats in Example 3

[0055] Serum collection and Elisa detection

[0056] The blood sample of the abdominal aorta of the rat was collected under sodium pentobarbital anesthesia. After the blood was naturally coagulated at room temperature for 30 min, it was centrifuged at 1000xg at 4°C for 15 min, and the supernatant was stored at -20°C. Subsequently, the concentration of ANP, BNP, IL18 and TNF-α in the serum was determined according to the related instructions using the ELISA kit purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd.

[0057] As Figure 7As shown, the ANP level of the Model group was significantly higher than that of the Control group, indicating that the myocardial wall tension increased or the volume load was too heavy. The BNP level was significantly higher, indicating severe ventricular dilation or damage. The ANP and BNP levels of the medium-dose and high-dose groups (F-M and F-H) of the traditional Chinese medicine composition were significantly reduced, indicating that the traditional Chinese medicine composition can protect heart function. The TNF-α level of the Model group was significantly higher than that of the Control group, indicating that the inflammation level of the mice increased significantly. The TNF-α level of the medium-dose and high-dose groups (F-M and F-H) of the traditional Chinese medicine composition was significantly lower than that of the Model group, indicating that the anti-inflammatory effect of the traditional Chinese medicine composition may be its core mechanism. The IL18 level of the Model group was significantly higher than that of the Control group. The IL18 level of the medium-dose and high-dose groups (F-M and F-H) of the traditional Chinese medicine composition was significantly lower than that of the Model group, indicating that the traditional Chinese medicine composition may play a role by inhibiting inflammasome activation. The above data indicate that the traditional Chinese medicine composition can inhibit inflammation caused by right ventricular heart failure of pulmonary arterial hypertension, reduce myocardial damage, and protect heart function.

[0058] Obviously, the above embodiments of the present application are only examples for clearly illustrating the present application, and are not intended to limit the embodiments of the present application. Based on the above description, other different forms of changes or variations can be made by those skilled in the art. Here, all the embodiments are not required to be exhausted, and the changes or variations that are obviously extended from the spirit of the present application are still within the protection scope of the present application.

Claims

1. A traditional Chinese medicine composition for treating pulmonary hypertension and right heart failure, characterized in that, The traditional Chinese medicine composition is prepared from raw materials including safflower, Japanese knotweed, lepidium seed, mulberry bark, and astragalus.

2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from 6-15 parts by weight of safflower, 6-15 parts by weight of Polygonum cuspidatum, 8-20 parts by weight of Lepidium apetalum, 10-30 parts by weight of Morus alba root bark, and 10-30 parts by weight of Astragalus membranaceus.

3. The traditional Chinese medicine composition according to claim 2, wherein the traditional Chinese medicine composition is prepared from 10 parts by weight of safflower, 10 parts by weight of Polygonum cuspidatum, 12 parts by weight of Lepidium apetalum, 15 parts by weight of Morus alba root bark, and 15 parts by weight of Astragalus membranaceus.

4. The traditional Chinese medicine composition according to any one of claims 1-3, wherein the traditional Chinese medicine composition is prepared by a method comprising the following steps: weighing the required amount of medicinal materials; decocting 2-4 times, each time adding 10-15 times the amount of water and decocting for 20-60 minutes; filtering and concentrating the decoction to a concentration of 2-3g of raw medicinal material per 1g extract.

5. The traditional Chinese medicine composition according to claim 4, wherein the traditional Chinese medicine composition is prepared by a method comprising the following steps: weighing the required amount of medicinal materials; decocting three times, each time adding 14 times the amount of water and decocting for 30 minutes; filtering and concentrating the decoction to 2.72g.

6. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition further comprises a pharmaceutically acceptable excipient.

7. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is an oral liquid, compound preparation, decoction, pill, capsule, tablet, granule or powder.

8. Use of the traditional Chinese medicine composition according to any one of claims 1-7 in the preparation of a medicament for treating or preventing pulmonary hypertension and right heart failure.

9. The application according to claim 8, wherein the drug has one or more of the following effects: (1) Improves pulmonary artery hemodynamics; (2) Improve the structure and function of the right heart; (3) Reduce pathological damage to myocardial tissue; (4) Degree of collagen deposition and fibrosis; (5) Reduce serum levels of heart failure markers; (6) Reduce inflammation levels.

10. The application according to claim 9, wherein the heart failure biomarker is selected from ANP and / or BNP.

11. The application according to claim 8, wherein the reduction in inflammation level is a reduction in IL18 and / or TNF-α.

12. The method for preparing the traditional Chinese medicine composition according to any one of claims 1-7, characterized in that, The method includes: weighing the required amount of medicinal materials; decocting 2-4 times, adding 10-15 times the amount of water each time and decocting for 20-60 minutes; filtering and concentrating the decoction until each 1g extract contains 2-3g of raw medicinal materials.

13. The method according to claim 12, wherein the method comprises: Weigh the required amount of medicinal materials; decoct 3 times, adding 14 times the amount of water each time and decocting for 30 minutes each time; filter and combine the decoctions to concentrate 2.72g.

Images